MFLI, WDRP, MCKE, BMGP, ACCP, DVME, AMLM, XMDC, IGSM, FHAI, CYSG, IGNT, ADXS OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, October 1st

Our Stocks to Watch today include Muscle Flex Inc. (OTC: MFLI), Wanderport Corp. (OTC: WDRP), Morgan Creek Energy Corp. (OTCBB: MCKE), Biomagnetics Diagnostics Corp. (OTC: BMGP), Access Pharmaceuticals Inc. (OTCBB: ACCP), Diverse Media Group Inc. (OTC: DVME), American Lithium Minerals Inc. (OTCBB: AMLM), XTend Medical Corp. (OTC: XMDC), IGSM Group Inc. (OTC: IGSM), Fountain Healthy Aging Inc. (OTCBB: FHAI), CAPE Systems Group Inc. (OTC: CYSG), Ingen Technologies Inc. (OTC: IGNT) and Advaxis Inc. (OTCBB: ADXS).

 

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.

 

MUSCLE FLEX INCORPORATED (OTC: MFLI)

"Up 11.11% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/MFLI.php

 

Company Profile: http://www.otcpicks.com/muscle-flex-inc.htm

 

Muscle Flex Inc. brings new products to market using direct response TV infomercials specializing in the health, fitness, wellness and hygiene sectors. As well, Muscle Flex Inc. develops and creates general television content for network and cable television distribution. Muscle Flex's corporate strategy is to develop new and innovative products for sale and distribution via its proprietary direct response marketing system and the creation of television media and shows for general network and cable broadcast.

 

MFLI News:

 

October 1 - Muscle Flex® to Produce and Air a Two-Minute Direct Response Commercial for the Muscle Flex VATA Brasil™ Sports & Active Wear Collection Ahead of Its 30 Minute Television Program

 

Muscle Flex Inc. (OTC: MFLI) announced that it will produce and air a 2-minute direct response commercial for its Muscle Flex VATA Brasil™ Sports & Active Wear Collection ahead of its 30 minute TV program. Muscle Flex expects to launch the Muscle Flex VATA Brasil™ Collection in October 2009 and the Exclusive Muscle Flex Premiere™ Collection by VATA Brasil™ early in the New Year. The Muscle Flex VATA Brasil 2 minute commercial will be a "drive to the internet" strategy that is intended to initiate substantial ecommerce revenue as well as introduce the sassy, sexy and exciting styles of this one-of-a-kind active wear collection. The Muscle Flex VATA Brasil 2 minute commercial will be aired in cities where the BUDDY Tablet Caddy™ and the Beagle StepFit™ have already established significant Muscle Flex brand awareness and loyalty to enhance revenue and website traffic numbers.

 

The Muscle Flex VATA Brasil and the exclusive Muscle Flex Premiere Collections are a OneFit™ garment that fits sizes 0-12 making it a perfect product for a direct response 2-minute and 30-minute television program. The specially designed VATA OneFit™ fabric is a lightweight, highly elastic fabric that has four times more filaments than regular fabric. The VATA OneFit fabric has a memory stretch quality which allows for its incredibly comfortable OneFit feature as well as natural wicking that uses no chemical treatments to draw the moisture from the skin to the surface where it quickly evaporates.

 

The Muscle Flex VATA Brasil 2-minute commercial will air prior to the full length 30 minute program which will showcase both the Muscle Flex VATA Brasil and the Exclusive Muscle Flex Premiere Collections. The 30-minute program, which is currently in development, will be an exciting showcase of both collections and will utilize 4 or 5 of today's high profile female celebrities. Danny Alex will host the 30-minute program and he promises that it will be a one-of-a-kind entertaining and inspiring showcase of both collections.

 

"The Muscle Flex VATA Brasil and the Muscle Flex Premiere lines are the hottest thing to hit female sports, fitness and casual apparel. We fully expect to capture significant market share in the female apparel category and grow that share exponentially," commented Danny Alex, CEO of Muscle Flex Inc. "The reaction to the lines has been phenomenal to say the least. During Emmy week, we had the opportunity to showcase and gift pieces from the line to a large number of celebrities and media and the response was truly amazing. In addition to the TV commercials, we have several high profile promotional events scheduled over the next few months that will truly propel both collections to the next level."

 

Muscle Flex signed an exclusive agreement with Houston PAD, master distributor for VATA Brasil™ for the development of two distinct sports & active wear collections:

 

The Exclusive Muscle Flex Premiere™ by VATA Brasil™ Collection: The Muscle Flex Premiere line shall be an exclusive, original, sassy and sexy female active wear line co-developed by Muscle Flex and the design team at VATA Brasil. To be launched in early 2010.

 

The Muscle Flex VATA Brasil Collection: This Collection shall be comprised of hand-picked pieces from the VATA Brasil collection that Muscle Flex shall co-brand with VATA Brasil. The collection shall encompass 15 - 18 pieces with an exclusive marketing agreement for the direct response marketing vehicle. To be launched in October 2009.

 

September 30 - The Muscle Flex/Sterling Worldwide Entertainment's Daytime Primetime TV Show 'Sugar Free' Garners Major Interest From Global Television Distributors

 

Muscle Flex Inc. (OTC: MFLI) (www.MuscleFlexInc.com) and Sterling Worldwide Entertainment, LLC (www.SterlingWWE.com), a subsidiary of Visual Industries, Inc., jointly announced today that their television show "Sugar Free," which is currently in pre-production, has received significant expressions of interest from global television program distributors and have engaged the interested media conglomerates in discussions regarding the show. Muscle Flex® and Sterling each hold a 50/50 ownership in "Sugar Free" and share equally in its future revenue streams. The companies are now in the final stages of pre-production for the TV pilot, which, upon completion, will be pitched to major television networks and national cable stations for North American and International distribution.

 

The initial interest is derived from the timely and compelling program content of "Sugar Free" as well as the strong relationships Sterling enjoys in the global television space. Interest in "Sugar Free" is not limited to the actual program broadcast but also extends to sales and distribution of the "Sugar Free" DVD series.

 

In an age where more than 21 million people (7% of the population) have diabetes and even more suffer from obesity and other illnesses, "Sugar Free" delivers real-life, practical solutions to anyone seeking to develop and maintain a healthy lifestyle. Hosted by a top-rated TV celebrity with a loyal fan base, "Sugar Free" takes a fun, in-your-face approach to demonstrating sugar-free recipes, exercises, and how to maintain a sugar-free life at work events, lunches, and dinners. In addition, celebrity guest appearances will add variety and depth to keep programming fresh on a daily basis.

 

"Revenue derived from a television program like Sugar Free can be significant. With the huge success of such TV shows as 'The Biggest Loser' and 'Celebrity Fit Club,' diet and exercise shows have been spun into television gold," said Danny Alex, CEO of Muscle Flex Inc. "'Sugar Free' has it all — the information, ideas and personalized motivation to help viewers get healthy and stay that way. The show is truly different — it's a cooking lesson, self-help talk show and reality TV all in one."

 

Kira Baskerville, CEO of Sterling Worldwide Entertainment, said, "'Sugar Free' will be a show that will help many people worldwide live healthier, longer lives. Sterling is excited to bring 'Sugar Free' to the international market place with Muscle Flex."

"Sterling not only possesses the talent and experience to develop an A-class daytime/primetime TV program but they also have long-standing relationships that can propel 'Sugar Free' into widespread distribution globally," commented Danny Alex, CEO of Muscle Flex Inc. "Sterling has successfully launched health and wellness TV shows globally, including the U.K., Europe and the U.S. 'Sugar Free' is one of Muscle Flex's best kept secrets and its potential has not been fully addressed by investors."

 

The overweight epidemic affects millions of people both young and old. As such, "Sugar Free" is expected to appeal to the 18- to 49-year-old demographic. However, as "self help" and "living a better life" resonates with persons of any age, the show is expected to reach an even broader audience in the U.S. Additional details of the show will be released at a future date in order to protect proprietary content, ideas and information.

 

ABOUT STERLING WORLDWIDE ENTERTAINMENT, LLC

 

Sterling Worldwide Entertainment, LLC, creates and delivers premium products in the entertainment market. Sterling enjoys relationships with award-winning producers, directors, and writers. Our relationships have expanded to include key financial institutions and distribution companies. It is Sterling's continued goal to create critically acclaimed work that also achieves commercial success and garners significant returns throughout the life of the film or project.

 

WANDERPORT CORPORATION (OTC: WDRP)

 

Detailed Quote: http://www.otcpicks.com/quotes/WDRP.php 

 

Company Profile: http://www.otcpicks.com/Newsletter/WDRP_eProfile_093009.html

 

Wanderport Corporation is a holding and business development company specializing in the investment and deployment of environmentally friendly technology such as, primary alternative renewable energy and energy saving products like electric vehicles which reduce global dependence on oil.

 

WDRP News:

 

October 1 - Wanderport One Step Closer to Product Production

 

Wanderport Corp. (OTC: WDRP) announced that, based on the recent letter of intent with Spain's leader in patented heating systems, Mr. Robert Simoneau, Head of Technological Research and Development has travelled to China to continue negotiations with manufacturers for a portion of Pulsar's productions.

 

"A final decision on manufacturing facilities is taking more time than expected due to the unanticipated letter of intent, its related constraints and manufacturing logistics complexities," stated Mr. Robert Simoneau.

 

"We have received numerous inquiries for product purchase and distribution from groups within many countries including the United States. As a result, this is a pivotal time for Wanderport's growth and therefore decisions must be taken without haste. We are fully committed to our business strategy while we respond to product demands, so that Wanderport may obtain its share of this multi billion dollar industry," further added Mr. Simoneau.

 

MORGAN CREEK ENERGY CORPORATION (OTCBB: MCKE)

"Up 5.56% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/MCKE.php 

 

Company Profile: http://www.otcpicks.com/morgan-creek-energy.htm 

 

Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties. For further information, see www.morgancreekenergy.com.

 

MCKE News:

 

September 24 - Morgan Creek Energy Takes Control and Majority Interest in Frio Draw Prospect in Curry County, New Mexico

 

Morgan Creek Energy Corp. (OTCBB: MCKE) (M6C1-Frankfurt) (the "Company") has taken control of the exploration of the Frio Draw prospect in Curry County, New Mexico. The Company had previously entered an agreement with FormCap, which was to act as a joint-venture partner on the project, but could not meet the requirements as set forth under the agreement.

 

Morgan Creek Energy will now retain a 100% interest in the 13,252-acre Frio Draw Prospect and intends to fund exploration drilling on the prospect through alternative sources.

 

Company President Peter Wilson states, "We have seen a tremendous upswing in the energy markets while drilling costs have gone down drastically. This gives Morgan Creek Energy the opportunity to fund its own drilling initiatives and therefore control the entire process."

 

Following a planned initial well drilling and completion, Morgan Creek Energy's management team expects to establish a set of drilling initiatives on the Frio Draw based on technical data and drill results.

 

BIOMAGNETICS DIAGNOSTICS CORPORATION (OTC: BMGP)

"Up 6.45% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/BMGP.php 

 

Company Profile: http://www.otcpicks.com/biomagnetics-diagnostics/biomagnetics-diagnostics.htm

 

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company’s revolutionary diagnostic systems, which are based on advanced magnetics, test for any viral or bacterial disease using any body fluid. The Company's technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test. The HTS-MTP platform is designed to detect the actual virus and viral load in body fluids and not just simply screen for the presence of viral antibodies.

 

BMGP News:

 

September 28 - Biomagnetics Diagnostics Receives a Financing Commitment up to $1 Million to Speed Development of Malaria Testing Technology

 

Equity investment provided by investors and anonymous philanthropic source

 

Biomagnetics Diagnostics Corp. (OTC: BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing, announced it has received a equity-based financing commitment up to $1 million from investors and an anonymous philanthropic source. These funds will be used to further develop the company’s unique handheld testing platform targeting the areas of malaria and bovine tuberculosis testing.

 

“We are very excited to be receiving this equity investment as it shows the significant commitment of our investors to furthering our corporate goals," commented Clayton Hardman, CEO of Biomagnetics Diagnostics. “We view our technologies as potentially revolutionizing pathogen testing in a variety of important markets. Our first goal is to finalize our government laboratory partnership, which we believe will be occurring over the coming weeks. We will then use these new funds to quickly move this technology into the field where we believe a significant market exists. We have already landed our first commitment from China's third largest dairy and we believe many other organizations are eagerly awaiting our market entry.”

 

According to the World Health Organization, some 3.2 billion people, or about half the world's population is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. In the case of malaria, early detection substantially improves treatability and survivability. TB (tuberculosis) is the second leading cause of death from infectious disease worldwide. Bovine TB is a growing problem through out the world with an estimated 1.3 billion cattle at risk. In the United States, where the cattle industry is valued at $60 billion annually, the use of existing diagnostic tests currently add $5.00 to $15.00 on average per head to the cattle industry's costs. Field deployable integrated optical biosensor systems hold the promise to significantly speed the diagnostic testing process and to meaningfully lower costs.

 

ACCESS PHARMACEUTICALS INCORPORATED (OTCBB: ACCP)

 

Detailed Quote: http://www.otcpicks.com/quotes/ACCP.php 

 

Company Profile: http://www.otcpicks.com/access-pharmaceuticals/access-pharmaceuticals.htm 

 

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.

 

ACCP News:

 

September 11 - Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States

 

Access Pharmaceuticals Inc. (OTCBB: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

 

In a comparison of cancer patients receiving standard oral mucositis care with those patients receiving MuGard , MuGard has been shown to significantly reduce the incidence and severity of the debilitating side effect of radiation treatment and chemotherapy.

 

Access has contracted with Accupac, Inc. to serve as its commercial manufacturer of MuGard in North America. Accupac manufactures, fills and packages a wide range of consumer commodity, over-the-counter (OTC) and prescription (Rx) products for the world's largest pharmaceutical and consumer products companies.

 

"Access is moving forward with the development of MuGard in North America," said Jeffrey B. Davis, Access' President & CEO. "Establishing our relationship with Accupac, a leader in liquid contract manufacturing, is critical to our successful commercialization of MuGard. In addition, Access is currently evaluating potential eMarketing partners as well as potential co-promotion or other licensing opportunities."

 

Access intends to use the initial batches of MuGard in connection with one or more market seeding studies to be conducted in the U.S. pursuant to protocols that are currently being developed. Access hopes to finalize these protocols and begin one or more market seeding studies in Q4 2009.

 

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop symptoms. MuGard is currently being marketed in the United Kingdom, Germany, Italy, Norway and Greece by Access' partner, SpePharm.

 

Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide.

 

DIVERSE MEDIA GROUP INCORPORATED (OTC: DVME)

 

Detailed Quote: http://www.otcpicks.com/quotes/DVME.php

 

Company Profile: http://otcpicks.com/Newsletter/DVME_eProfile_091709.html  

 

Diverse Media Group, Inc. (OTC: DVME) is an entertainment company that aggregates expertise across all aspects of the media industry. Diverse Media Group has at its core the established 27-year history of its wholly owned subsidiary, Diverse Talent Group. Diverse Talent Group is now the 10th largest Hollywood agency offering talent and literary representation in commercials, episodic television, cable programming and motion pictures. The company has the ability to create programming, foster distribution and represent talented individuals to fuel a new digital age of content generation. The parent company also includes the subsidiary Talent Quest America, Inc., which identifies new and rising talent representing the future of the Hollywood entertainment community.

 

DVME News:

 

September 28 - Network Talks Underway to Develop 'Momo' into Weekly TV Series Title is Part of Diverse Media Group, Inc. Option Agreement with Elio Pictures

 

“Momo” executive producers Dimitri Logothetis and Nicholas Celozzi have announced that talks are underway with networks in the U.S. and Canada to develop the project as a weekly series for television. “Momo” is one of six titles for which Diverse Media Group, Inc. (OTC: DVME) has optioned to purchase a 30% interest from Elio Pictures, Ltd.

 

Diverse Media Group CEO Chris Nassif calls the development “a huge step forward in our company’s transition to a complete entertainment and media services provider.”

 

Logothetis and Celozzi have been working for seven years on the life story of infamous mob boss Sam Giancana. After securing the exclusive story rights from Francine Giancana to her father’s life story, they originally set the project up at Warner Bros. and Turner as a mini-series. Logothetis calculates development costs to date at $75,000. With the success of the 60's-based AMC series “Mad Men,” they decided that “Momo” could also satisfy weekly audience interest in that period of Americana. Giancana was born in 1908 and killed in 1974.

 

Celozzi describes the series as real-life “Sopranos” meets “The Gangster Chronicles.” Sam Giancana was a very compelling personality. As a family man, Sam lost his wife to a rheumatic heart disease, raised three daughters, supported an extended family and was one of the most powerful men of the twentieth century. Through union ties Giancana helped swing the Illinois vote during the Kennedy/Nixon election. He was the first mobster to claim his rights to the Fifth Amendment in front of live television cameras while questioned by Bobby Kennedy during the McClellan committee hearings. Sam had a long-standing friendship with Frank Sinatra, the leader of the so called “Rat Pack,” who played in Chicago nightclubs run by Giancana.

 

The other Elio Pictures titles optioned by Diverse Media Group include “The Lost Angel” (2005) with Judd Nelson and Celozzi, “Framed by Seduction” (2004) starring Robert Patrick, “Nightmare Boulevard” (2004) starring Claudia Christian and Corbin Bernsen, “7-10 Split” (2007) featuring Tara Reid and Rachel Hunter, and “Senior Skip Day” (2008) with Lea Thompson and Norm MacDonald.

 

The option is being purchased with 25 million shares of Diverse Media Group restricted common stock, valued at $50,000. The Company has until March 30, 2010, to exercise its option for a cash price of an additional $400,000.

 

AMERICAN LITHIUM MINERALS INCORPORATED (OTCBB: AMLM)

"Up 3.73% in morning trading"

 

Detailed Quote: www.otcpicks.com/quotes/AMLM.php 

 

Company Profile: http://otcpicks.com/Newsletter/AMLM_100109.html 

 

American Lithium Minerals Inc. is an early stage lithium exploration company engaged in evaluating, developing and acquiring lithium projects, with a focus on the USA.

 

AMLM News:

 

September 29 - American Lithium Minerals Inc. Appoints Former Vice-Chairman of Merrill Lynch Canada, Mr. Hugh Aird, Vice President of Business Development

 

American Lithium Minerals Inc. (OTCBB: AMLM) (the "Company") announced the appointment of Mr. Hugh Aird as Vice President of Business Development.

 

Mr. Aird, former Vice-Chairman of Merrill Lynch Canada, has joined American Lithium Minerals and will head up further Merger and Acquisitions pursuits for the company. Since graduating from Harvard University, Mr. Aird has held numerous top level executive positions throughout the financial industry. He will now work closely with American Lithium Minerals management and the board of directors to help develop and execute the company's growth strategy. "My research tells me that Lithium is the next explosive growth sector and after researching many of the companies in this space I feel very confident that American Lithium Minerals is the best positioned," stated Mr. Aird. "The vast opportunities available for American Lithium Minerals during this all important positioning phase of the rapidly escalating Lithium and Rare Earth minerals industry are exciting to me and I look forward to helping in any way I can."

 

"We could not be more pleased with Mr. Hugh Aird's decision to join our outstanding management team," said Matthew Markin, President of American Lithium Minerals. "Hugh's tremendous Business Development and Investment Banking experience will be instrumental in ensuring American Lithium Minerals continues to maintain a leadership position."

 

XTEND MEDICAL CORPORATION (OTC: XMDC)

"Up 150.00% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/XMDC.php 

 

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.

 

XMDC News:

 

October 1 - XTend Medical Signs Letter of Intent to Merge With BioHarp, Korea Combined Resources to Target Global Health Markets

 

XTend Medical Corp. (OTC: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, announced today the company has signed a Letter of Intent to Merge with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device. Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number. The share structure of the company will remain in effect with no changes anticipated.

 

BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body's organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases. This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.

 

Unlike CT Scans, MRIs and other similar testing devices, the BioHarp penetrates to the cellular level to detect inflammation differences in the cells. The resulting scan of the body can detect early disease states such as diabetes, liver damage, and other organ problems that, when treated at this early stage, can assist managed care companies, physicians, and insurance companies in increasing morbidity rates and lowering health costs significantly.

 

The U.S. National Science Foundation has predicted that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare.

 

"The management at XTend has been working diligently on this merger for the past 9 months to insure we create a powerful opportunity for the company to have a clear manufacturing partner, cutting-edge medical device, and the market whereby we can sell this device globally to healthcare organizations and countries looking to detect early signs of diseases that will save lives and lessen costs associated with treating these diseases," stated Mr. Paul Lisenby, CEO of XTend Medical. Mr. Lisenby further states, "The BioHarp has gone through several revisions and is now ready to go into full production. The device is not only intended for humans, but the application has shown that animals can benefit from this technology as well. Our goal is to get this device into the hands of physicians, veterinarians, and other professionals that understand the technology can detect, on a molecular level, inflammation that can lead to serious health problems. We will market this product aggressively and have already been contacted by several countries in Asia and Europe that are interested in making the BioHarp part of their national healthcare program. We're very excited to work closely with the doctors and scientists associated with the BioHarp unit in Korea to continue to upgrade the unit for potential use by the general public. We expect to finalize this merger in the next thirty to sixty days."

 

IGSM GROUP INCORPORATED (OTC: IGSM)

"Up 71.43% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/IGSM.php

 

Based in Florida, IGSM Group Inc. recently announced its intention to become a full reporting company and operate Digital Television Channels in Florida. In addition, IGSM recently acquired a Television Library of Programs. IGSM also offers a suite of E-Learning products as part of its Digital Services.

 

IGSM News:

 

September 30 - IGSM Outlines Large-Scale Webinar Platform

 

IGSM Group Inc. (OTC: IGSM) outlines its large-scale webinar platform, the first of a series of E-Learning products.

 

IGSM Group Inc.outlined its Large-Scale webinar platform aimed at the corporate or repeat user who uses webinars on a regular basis. Whether they need 100, 500 or 1000 people on an interactive session IGSM can fulfill their needs.

 

"Our niche is to provide full service to the most demanding users. Whether they are corporate trainers or focused on end user education, they need a full service company," said H. Francis Fytton, CEO of IGSM. "Working closely with several content providers has enabled us to add the features they need and don't have from existing providers," added Fytton.

 

IGSM Group Inc.has previously announced that it will provide Distance Learning Solutions including TeleSeminars and Webinars. E-Learning or Distance Learning products have become more popular as corporations seek to reduce overhead by eliminating travel and meeting costs.

 

FOUNTAIN HEALTHY AGING INCORPORATED (OTCBB: FHAI)

"Up 22.58% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/FHAI.php 

 

Fountain Healthy Aging is a company specifically focussed in the anti aging industry, which is one of the quickest growing industry sectors worldwide. We have a range of products targeted at the anti-aging market, including our revolutionary flagship product Vitalife, which we believe is ready to make a massive impact in the anti-aging industry. We recognize the importance of the anti-aging sector, an emerging dynamic within the overall health and wellness revolution. We believe that we are uniquely positioned to capitalize on this rapidly growing trend, first with our unique flagship product, rapidly followed by our other products which have been specifically developed for this market. Fountain Healthy Aging's main focus is on the specialty, premium product category, which is a growing segment of the market that provides gross margins significantly higher that the lower-priced, mainstream health products market.

 

FHAI News:

 

September 30 - Fountain Healthy Aging Inc. to Commence Lawsuits Claiming Over US$210,000,000 Against Dunn Capital Partners, Michael Bailey and Gowling Lafleur Henderson

 

Fountain Healthy Aging Inc. (OTCBB: FHAI) announced on September 30, 2009 that it is commencing legal proceedings against Dunn Capital Partners, its principal, Michael Bailey, its legal counsel, Gowling Lafleur Henderson (Gowlings) and others for a recovery of damages to the Company and its shareholders.

 

The claim arises as a result of the default by Dunn Capital Partners in making payments due to the Company under the terms of the agreement entered into between the Company, Oak Resources Limited and Dunn Capital Partners dated 29 July 2009 (the "Agreement"); the breach by Gowlings of the terms of an agreement under which it would hold stock certificates in the Company in escrow pending payment by Dunn Capital Partners and; the diminution of the value of the Company's stock as a direct result of the trading activities of Dunn Capital Partners using stock which it had acquired without any payment being made in respect of such stock.

 

The Company will be requesting a damage award of US$9.6 Million in respect of amounts due to the Company from Dunn Capital Partners under the Agreement and US$201 million for the loss in value of the Company's stock and its business as a result of the activities of Dunn Capital Partners and Gowlings. If its claims are successful, it is the Company's intention to declare a special dividend to shareholders and institute a strong stock buy back program on the open market.

 

Furthermore, if the claims are successful, it is the intention of the Company that a minimum of 50% of the amount recovered will be reinvested into the Company to fully finance the Company's business activities, with the intention of restoring full value to the Company, its shareholders and its stock price.

 

Fountain CEO, Paul Hunston, commented "we have worked very hard to try to bring about an amicable resolution of this dispute, but throughout we have repeatedly been faced with misrepresentations made by Michael Bailey concerning payment and his trading activities, which misrepresentations have been exacerbated by the activities of Dunn Capital Partner's attorneys Gowlings, and the partner acting as escrow agent, Michael Boehm. In particular, the damages suffered have been exacerbated by the release by Gowlings to Dunn Capital Partners of stock certificates in the Company in direct contravention of an agreement under which Gowlings had accepted such certificates as escrow agents pending receipt of payments already due to the Company from Dunn Capital Partners."

 

Mr Hunston continued: We have been advised by Dunn Capital Partners that all of the stock received by them, and for which no payments were made, was immediately sold in the market in clear breach of the Agreement and to the detriment of the Company's stock price. We are in the process of retaining legal counsel, and will be filing claims against all parties for losses suffered by the Company, as well as exemplary and punitive damages arising from the wilful conduct of Michael Bailey and Michael Boehm in this matter. In all of this, I have been and will continue to be mindful of our loyal shareholders and am determined to try and minimize or eliminate losses suffered as a result of the actions of the defendants."

 

Finally, Mr Hunston stated: "Obviously, this lawsuit is a distraction for management, which I would have preferred to avoid. However, we have a strong management team and I will not allow this distraction to deflect us from our business goals, which we remain on course to achieve and about which further announcements will be made in the coming weeks. However, I feel that it is in the clear best interests of the Company and all of its shareholders to pursue this legal action and we will pursue it until justice has been done."

 

CAPE SYSTEMS GROUP INCORPORATED (OTC: CYSG)

"Up 40.00% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/CYSG.php

 

CAPE Systems is an international provider of supply chain management technologies. CAPE Systems offers a comprehensive range of software systems and tools, from packaging and pallet optimization software, RFID asset tracking, to integrated warehouse and inventory management solutions, pick-to-light systems, and transportation management systems for enterprise wide and collaborative supply chain optimization.

 

CYSG News:

 

September 24 - CAPE Systems Selected as an Inbound Logistics Top 100 Logistics IT Provider for 2009

 

CAPE Systems Group, Inc. (OTC: CYSG), a leading provider of software technology for packaging design, pallet optimization, RFID Asset Tracking, inventory and warehouse management, supply chain execution and order fulfilment, announced that once again it has been awarded the prestigious "Inbound Logistics Top 100 Logistics IT Provider 2009" for a sixth consecutive year.

 

The Company credits its robust spectrum of supply-chain solutions, timely development and implementation of technologies and continuous investment in enhancements and upgrades as reasons for the Company's technological strength and continued growth. CAPE Systems' commitment is to research and understand profoundly the ever changing needs of our customers. Thus, we strive to position CAPE to meet, if not anticipate, the demanding specifications of our strong blue chip customer-base.

 

INGEN TECHNOLOGIES INCORPORATED (OTC: IGNT)

"Up 34.15% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/IGNT.php

 

Ingen Technologies, Inc. is the leading world manufacturer of gravity-independent in-line oxygen flow meter products and services related to pulmonary and respiratory therapeutic hospital and home oxygen therapy. The company has adopted quality improvement (QI) initiatives throughout all areas of operations. Ingen Technologies is registered with the Food & Drug Administration, and licensed in good standing with the Department of Health Services. Headquartered in Yucaipa, California, the company distributes its respiratory products in North America, Asia and European Communities, and its operations provide sales, logistics, billing and collections. Supported by corporate functions such as Finance, Information Services, Human Resources, Legal and Contract Services, Ingen Technologies division and regional business units are able to respond quickly to customer and patient needs.

 

IGNT News:

 

October 1 - Ingen China Patent is Now Issued and Published

 

Ingen Technologies, Inc. (OTC: IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the Company has received notification from its patent attorney, Donn Harms, regarding the publication of the Chinese patent for the Oxyview and the Oxyview Nasal Cannula.

 

The designated Chinese patent application no. 200710005067.4 was officially issued and published on July 1, 2009 for the cannula gas flow meter referred to as "Oxyview".

 

The company's pending patents in Japan, Canada, and the European Communities are expected to issue in 2010.

 

Donn K. Harms is a Registered Patent Attorney also handling business and corporate law matters since 1988, with heavy emphasis on trademarks, copyrights, patents, and licensing matters. Mr. Harms is certified by the San Diego County Bar Association for trademarks, and is a former member of the American Bar Association Committee on Trademark Law for recommendations to the U.S. Congress. His San Diego based firm, American Patent and Trademark Law Center, is a professional association of independent registered patent attorneys and specializes in patent, trademark, copyright and related business and government contract matters with agents and associates throughout the world, including China and Russia, providing various types of domestic and international filing needs for their clients. The firm is registered to practice before the United States Patent & Trademark Office.

 

"Mr. Harms has been our patent attorney since 1997, and has effectively provided his services that have allowed for several issued patents, domestic and foreign. You could not find a more successful firm and patent attorney than Donn Harms. Our patents provide a higher valuation of our company and additional security to our intellectual property, specifically our new "gravity-independent" technology applied to the Oxyview products, and our "digital transmission" technology applied to our OxyAlert products. The world market for our products includes 600M patients requiring supplementary oxygen and home oxygen therapy. We have recently shown increased sales in the USA with demand of our Oxyview Nasal Cannula products, and we have the company positioned to enter markets in China, Europe, Japan, Canada and Australia for product distribution in early 2010 as an additional revenue stream for Ingen," stated Scott R. Sand, CEO and Chairman of the Board.

 

ADVAXIS INCORPORATED (OTCBB: ADXS)

"Up 21.43% in morning trading"

 

Detailed Quote: http://www.otcpicks.com/quotes/ADXS.php

 

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

 

ADXS News:

 

October 1 - Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection

 

23% of Cervix Cancer Patients Treated with ADXS11-001 Remain Alive 36 Months After Initial Dosing

 

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

 

The patients had participated in the first human trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer in women who have failed prior cytotoxic treatment. Advaxis is tracking the survival of these patients at three (3) month intervals.

 

These mortality figures substantially exceed the median survival rate established by the National Cancer Institute's Gynecologic Oncology Group (GOG), which varies between 3.8 and 6.2 months in studies of patients who have failed prior cytotoxic treatment including chemotherapy with various agents (GOG Protocol #127).

 

Earlier this year, Advaxis published in the medical journal Vaccine the fact that four (4) of thirteen (13) evaluable patients, treated with ADXS11-001, experienced tumor reductions, two (2) patients had their lesions disappear and fifty-three percent (53%) survived more than one (1) year; thus, posting a median survival rate of 347 days. Although this trial was designed to assess safety, not efficacy or survival, three (3) of the thirteen (13) patients or twenty-three percent (23%) evaluable for efficacy are still alive at over 1,000 days, post-dosing with the study drug, as of September 29, 2009.

 

ABOUT THE ADXS11-001 IMMUNOTHERAPY

 

ADXS11-001 is a therapeutic vaccine, unlike currently marketed prophylactic vaccines, that treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today.

 

Earlier this year, the US Food and Drug Administration (FDA) granted Advaxis an IND for a Phase II clinical trial in human papilloma virus- (HPV) caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous and a precursor to cervix cancer.

 

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

 

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

 

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

 

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

 

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

 

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.

 

Disclosure: OTCPicks.com has been compensated three thousand five hundred dollars from Dana Alex for MFLI advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by a third party for WDRP advertising and promotional services. OTCPicks.com has been compensated two thousand five hundred dollars from a non-controlling third Party (BlueWave Advisors) for MCKE advertising and promotional services. OTCPicks.com has been compensated seven thousand five hundred dollars by a third party for BMGP advertising and promotional services. OTCPicks.com has been compensated ten thousand dollars by the company for a current BMGP advertising and promotional services. OTCPicks.com has been compensated eight thousand five hundred dollars from a third party (Longview Communications Corp.) for ACCP advertising and promotional services. OTCPicks has been compensated ten million free trading shares from a non-controlling third Party (Microcap Management) for DVME advertising and promotional services. OTCPicks.com has been compensated three thousand dollars by Lake Group Media for distribution of an AMLM e-mail advertisement. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.